Used in cancer immunotherapy to enhance anti-tumor immune responses by blocking the LAG-3 (lymphocyte activation gene-3) receptor on T cells. Inhibiting LAG-3 prevents it from suppressing T cell activity, allowing the immune system to more effectively recognize and attack tumor cells. Often explored in combination with other immune checkpoint inhibitors, such as anti-PD-1 antibodies, to improve clinical outcomes in solid tumors including melanoma, non-small cell lung cancer, and other advanced cancers. Supports the restoration of exhausted T cell function within the tumor microenvironment, contributing to durable immune activation. Currently utilized as a reference in preclinical and clinical development of LAG-3-targeting therapies.